tiprankstipranks
Advertisement
Advertisement

TSE:GILD Stock Latest News

Gilead price target raised to $175 from $171 at Morgan Stanley
The FlyGilead price target raised to $175 from $171 at Morgan Stanley
3d ago
GILD
MacroGenics upgraded to Buy at B. Riley after deal for Tubulus
PremiumThe Fly
MacroGenics upgraded to Buy at B. Riley after deal for Tubulus
3d ago
GILD
MGNX
Tempus AI announce strategic collaboration with Gilead
PremiumThe Fly
Tempus AI announce strategic collaboration with Gilead
4d ago
TEM
GILD
Kymera Therapeutics announces Gilead option exercise to license KT-200
PremiumThe Fly
Kymera Therapeutics announces Gilead option exercise to license KT-200
4d ago
GILD
KYMR
Gilead price target raised to $155 from $152 at Truist
PremiumThe Fly
Gilead price target raised to $155 from $152 at Truist
5d ago
GILD
Gilead price target raised to $155 from $152 at Truist
PremiumThe FlyGilead price target raised to $155 from $152 at Truist
5d ago
GILD
Balancing Strategic Oncology Expansion and Execution Risk: Why Gilead’s Tubulis Deal Supports a Hold Rating
Premium
Ratings
Balancing Strategic Oncology Expansion and Execution Risk: Why Gilead’s Tubulis Deal Supports a Hold Rating
5d ago
GILD
Gilead Sciences: Strategic Oncology Expansion and Undervalued Growth Opportunity Driving Buy Rating
Premium
Ratings
Gilead Sciences: Strategic Oncology Expansion and Undervalued Growth Opportunity Driving Buy Rating
5d ago
GILD
Gilead’s Tubulis Acquisition: Building an ADC Oncology Franchise and Enhancing Risk‑Reward for GILD Shares
PremiumRatings
Gilead’s Tubulis Acquisition: Building an ADC Oncology Franchise and Enhancing Risk‑Reward for GILD Shares
5d ago
GILD
Leerink says Tubulis deal highlights value of ADC platforms like Sutro’s
PremiumThe Fly
Leerink says Tubulis deal highlights value of ADC platforms like Sutro’s
5d ago
GILD
IMNM
Leerink sees Gilead’s $5B Tubulis buy as ‘more than an oncology bolt-on’
PremiumThe Fly
Leerink sees Gilead’s $5B Tubulis buy as ‘more than an oncology bolt-on’
5d ago
GILD
Gilead price target raised to $123 from $118 at RBC Capital
PremiumThe Fly
Gilead price target raised to $123 from $118 at RBC Capital
5d ago
GILD
Gilead to acquire Tubulis for $3.15B upfront, up to $1.85B in milestone payments
PremiumThe FlyGilead to acquire Tubulis for $3.15B upfront, up to $1.85B in milestone payments
6d ago
GILD
Compugen initiated with a Buy at Lake Street
Premium
The Fly
Compugen initiated with a Buy at Lake Street
6d ago
AZN
MRK
Assembly Biosciences price target raised to $43 from $39 at Guggenheim
Premium
The Fly
Assembly Biosciences price target raised to $43 from $39 at Guggenheim
7d ago
ASMB
GILD
Gilead extends tender offer to acquire Arcellx
PremiumThe Fly
Gilead extends tender offer to acquire Arcellx
11d ago
ACLX
GILD
Galapagos, Gilead enter pact to collaborate on T cell engager therapies
PremiumThe Fly
Galapagos, Gilead enter pact to collaborate on T cell engager therapies
13d ago
GILD
GLPG
Clear Street says Gilead-Ouro deal highlights upside for Cullinan’s velinotamig
PremiumThe Fly
Clear Street says Gilead-Ouro deal highlights upside for Cullinan’s velinotamig
19d ago
CGEM
GILD
Galapagos in partnership discussions with Gilead after Ouro deal
PremiumThe Fly
Galapagos in partnership discussions with Gilead after Ouro deal
20d ago
GILD
GLPG
Gilead to acquire Ouro Medicines
PremiumThe FlyGilead to acquire Ouro Medicines
20d ago
GILD
Gilead to acquire Ouro Medicines for $1.675B
Premium
The Fly
Gilead to acquire Ouro Medicines for $1.675B
20d ago
GILD
Gilead near acquisition of Ouro Medicines for up to $2B, FT reports
Premium
The Fly
Gilead near acquisition of Ouro Medicines for up to $2B, FT reports
20d ago
GILD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >